Tuesday's Early Winners & Losers
Shares of Sanmina-SCI (SANM) sank in late trading Monday after the electronics-manufacturing services company lowered its third-quarter estimates.
The company expects earnings for the recently ended quarter to be 6 cents to 7 cents a share, before items. Its previous forecast called for earnings of 8 cents to 10 cents a share. Sanmina estimates that third-quarter revenue totaled $2.71 billion, at the bottom of its guidance of $2.7 billion to $2.8 billion. Analysts polled by Thomson First Call had an average estimate for earnings of 9 cents a share on $2.75 billion in revenue. The company attributed the shortfall to a less-favorable product mix, lower-than-expected profitability in its computing business, and slower-than-anticipated improvement in its enclosure business. Shares tumbled 65 cents, or 15%, to $3.62 in after-hours trading.
Neurocrine Biosciences (NBIX) posted a wider second-quarter loss that missed analysts' estimates, sending its shares lower after hours. The company recorded a loss of $27.4 million, or 73 cents a share, compared with a loss of $5.6 million, or 15 cents a share, a year earlier. Revenue dropped to $9.2 million from $33.2 million a year earlier. Wall Street anticipated a loss of 72 cents a share and revenue of $22.9 million. Neurocrine attributed the drop in revenue to lower revenue recognized under collaborative agreements.
Neurocrine also reiterated that it will need to conduct more clinical trials for the insomnia drug Indiplon, and that it might need more tests for the immediate-release version. In May, the Food and Drug Administration delayed approving an immediate-release version of Indiplon and rejected a long-acting version of the drug. Neurocrine on Monday said it now expects a loss of more than $130 million for 2006, with a net cash burn of $100 million. Shares fell 33 cents, or 3.5%, to $9.09 in late trading.Shares of Pharmaceutical Product Development (PPDI) advanced after the contract-research company posted second-quarter results that beat Wall Street's expectations. The company posted a profit of $36.4 million, or 31 cents a share, up from $20.8 million, or 18 cents a share a year ago. Revenue climbed 26% to $309 million. Analysts on average projected earnings of 29 cents a share and revenue of $274.5 million in revenue. After hours, shares rose $2.31, or 6.4%, to $38.27.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV